Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDT NASDAQ:DRMA NASDAQ:GLTO NASDAQ:NMTR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTCDT Equity$0.61-2.6%$1.80$0.57▼$274.80$1.91M1.921.81 million shs7.46 million shsDRMADermata Therapeutics$5.50+6.0%$6.27$5.04▼$24.90$3.54M0.5622,334 shs78,547 shsGLTOGalecto$2.98+15.5%$3.38$2.01▼$14.82$3.42M1.35129,196 shs1.94 million shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTCDT Equity-21.57%-52.99%-66.21%-75.29%-99.67%DRMADermata Therapeutics-1.33%-10.21%-17.49%-32.95%-68.16%GLTOGalecto-16.50%-14.00%-23.67%-23.89%-77.43%NMTR9 Meters Biopharma0.00%0.00%0.00%-99.72%-81.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTCDT Equity$0.61-2.6%$1.80$0.57▼$274.80$1.91M1.921.81 million shs7.46 million shsDRMADermata Therapeutics$5.50+6.0%$6.27$5.04▼$24.90$3.54M0.5622,334 shs78,547 shsGLTOGalecto$2.98+15.5%$3.38$2.01▼$14.82$3.42M1.35129,196 shs1.94 million shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTCDT Equity-21.57%-52.99%-66.21%-75.29%-99.67%DRMADermata Therapeutics-1.33%-10.21%-17.49%-32.95%-68.16%GLTOGalecto-16.50%-14.00%-23.67%-23.89%-77.43%NMTR9 Meters Biopharma0.00%0.00%0.00%-99.72%-81.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTCDT Equity 0.00N/AN/AN/ADRMADermata Therapeutics 3.00Buy$10.0081.82% UpsideGLTOGalecto 3.00Buy$10.00235.57% UpsideNMTR9 Meters Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NMTR, CDT, GLTO, and DRMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025DRMADermata TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $10.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTCDT EquityN/AN/AN/AN/A($73.54) per shareN/ADRMADermata TherapeuticsN/AN/AN/AN/A$6.20 per shareN/AGLTOGalectoN/AN/AN/AN/A$10.99 per shareN/ANMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTCDT Equity-$17.80M-$435.00N/A∞N/AN/AN/A-350.23%11/12/2025 (Estimated)DRMADermata Therapeutics-$12.29M-$16.41N/A∞N/AN/A-214.98%-153.76%N/AGLTOGalecto-$21.44M-$13.13N/AN/AN/AN/A-115.70%-95.42%11/7/2025 (Estimated)NMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/ALatest NMTR, CDT, GLTO, and DRMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CDTCDT EquityN/A-$5.46N/A-$5.46N/AN/A8/13/2025Q2 2025DRMADermata Therapeutics-$2.90-$1.66+$1.24-$1.66N/AN/A8/5/2025Q2 2025GLTOGalectoN/A-$2.60N/A-$2.60N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDTCDT EquityN/AN/AN/AN/AN/ADRMADermata TherapeuticsN/AN/AN/AN/AN/AGLTOGalectoN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTCDT EquityN/A1.451.45DRMADermata TherapeuticsN/A6.476.47GLTOGalectoN/A4.964.96NMTR9 Meters BiopharmaN/A0.590.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTCDT Equity3.29%DRMADermata Therapeutics8.67%GLTOGalecto14.20%NMTR9 Meters Biopharma22.34%Insider OwnershipCompanyInsider OwnershipCDTCDT Equity7.72%DRMADermata Therapeutics18.50%GLTOGalecto10.80%NMTR9 Meters Biopharma2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTCDT Equity33.06 million2.83 millionNot OptionableDRMADermata Therapeutics8680,000556,000Not OptionableGLTOGalecto401.32 million1.18 millionOptionableNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataNMTR, CDT, GLTO, and DRMA HeadlinesRecent News About These CompaniesWhat is a prepayment meter?August 24, 2024 | uswitch.comUAfter coeliac fail, 9 Meters plots phase 3 in short bowel syndromeJuly 28, 2024 | pharmaphorum.comPEnergy firms likely to miss smart meter deadline, warns Which?December 14, 2023 | bbc.comBDeal reached to sell some assets of bankrupt Raleigh firmNovember 8, 2023 | bizjournals.com9 Meters Biopharma, Inc. (NMTRQ)November 7, 2023 | finance.yahoo.comTRACK AND FIELD/ Yamagata sets Japan record in 100-meter sprint with 9.95 secondsOctober 28, 2023 | asahi.comA9 Meters Biopharma Inc (NMTRQ)October 17, 2023 | investing.comVintage Meters Reborn As Steam Punk ClockOctober 10, 2023 | hackaday.comH9 Meters Biopharma (OTC: NMTR.Q)August 16, 2023 | fool.comInsider Sale Alert: 9 Meters Biopharma Inc. [NMTR] – Is it Time to sell?July 25, 2023 | knoxdaily.comK9 Meters Biopharma Inc. [NASDAQ: NMTR] Sees Decrease in Stock ValueJuly 21, 2023 | knoxdaily.comKRaleigh firm joins worrying trend of bankruptcies for drugmakersJuly 18, 2023 | bizjournals.comDrug developer 9 Meters Biopharma files for bankruptcy protectionJuly 18, 2023 | reuters.comWhy Are 9 Meters Biopharma Shares Nosediving Today?July 18, 2023 | finance.yahoo.comExamining the Potential Price Growth of 9 Meters Biopharma Inc. (NMTR)July 18, 2023 | knoxdaily.comKTemperato resigns as CEO of Raleigh drugmakerMay 30, 2023 | bizjournals.com9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel SyndromeMay 30, 2023 | finance.yahoo.com9 Meters Biopharma (NASDAQ: NMTR)May 27, 2023 | fool.comNMTR - 9 Meters Biopharma, Inc.May 25, 2023 | uk.finance.yahoo.comCitigroup Maintains 9 Meters Biopharma (NMTR) Neutral RecommendationMay 19, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNMTR, CDT, GLTO, and DRMA Company DescriptionsCDT Equity NASDAQ:CDT$0.61 -0.02 (-2.59%) Closing price 04:00 PM EasternExtended Trading$0.59 -0.02 (-3.12%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Dermata Therapeutics NASDAQ:DRMA$5.50 +0.31 (+5.97%) Closing price 03:56 PM EasternExtended Trading$5.52 +0.02 (+0.36%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Galecto NASDAQ:GLTO$2.98 +0.40 (+15.50%) Closing price 04:00 PM EasternExtended Trading$2.86 -0.12 (-3.86%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
